- Blocking Buffers systems, enabling patients with end-stage renal disease to manage treatment from home, are becoming increasingly vital in modern healthcare due to their ability to improve patient comfort, reduce hospital visits, and lower healthcare costs. These systems offer flexibility in scheduling, improved quality of life, and are being rapidly adopted in both urban and rural settings
- The accelerating demand for Blocking Buffers in the U.S. is primarily fueled by the rising prevalence of chronic kidney disease (CKD), increasing awareness of home-based renal care, technological advancements in compact and user-friendly dialysis machines, and growing support from insurance providers for at-home treatments
- U.S. dominated the blocking buffers market in North America with the largest revenue share of 42.8% in 2024. This is attributed to the country’s advanced healthcare infrastructure, strong presence of key market players such as Fresenius Medical Care and Baxter International, and supportive reimbursement policies. The U.S. market has also seen a surge in Blocking Buffers adoption due to patient preference for remote care, especially post-COVID-19, and initiatives by healthcare providers to decentralize dialysis services
- The liquid form segment dominated the blocking buffers market with a revenue share of 56.7% in 2024 due to its ease of use, minimal preparation time, and suitability for high-throughput laboratories
